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CD81TCR1 and CD81TCR2 Cells in Whole Bone Marrow
Facilitate the Engraftment of Hematopoietic
Stem Cells across Allogeneic Barriers
Although it requires 10- to 20-fold more allogeneic than
congenic cells to achieve the PD95 in a given setting,
only 2-fold more cells are required to reach given en-
graftment parameters at high doses: 5,000 congenic or
10,000 allogeneic HSC are required to obtain WBC and
Kimberly L. Gandy,*² Jos Domen, Hector Aguila,³
and Irving L. Weissman
Department of Pathology and Developmental Biology
Stanford University Medical Center
Stanford University
Stanford, California 94305 platelet engraftment by 10±11 days (Uchida et al., 1998).
Even at high doses of HSC, no mice develop GVHD. In
contrast to the congenic setting, non-HSC elements in
Summary the BM graft appear to have a role in allogeneic radiopro-
tection and donor-derived engraftment. Whereas 100
Although purified hematopoietic stem cells (HSC) are HSC and 2 3 105 BM (the amount of BM containing
sufficient to engraft irradiated allogeneic recipients, 100 HSC) can fully radioprotect and engraft congenic
bone marrow (BM) contains other cells that facilitate recipients, 500 HSC do not radioprotect to the degree
engraftment. Here, several candidate facilitators were of 1 3 106 BM in allogeneic recipients (10%±40% survival
tested by cotransplantation with HSC. Both TCR1 and versus 100%). The cells responsible for the differential
TCR2CD8a1 BM subpopulations have facilitative po- engraftment between the HSC and BM populations in
tential. CD81TCR1 cells are typical T lymphocytes. the allogeneic setting are the focus of this study.
CD81TCR2 facilitators are CD32, not CD31, have a Over the last decade, much effort has focused on
granular morphology, and are CD8b2 and CD11c1; characterization of cells expressing T cell markers with
they share phenotypic characteristics with CD8aa the hope of identifying a population that facilitates the
lymphoid dendritic cells and veto cells. We also dem- engraftment of hematopoietic cells across allogeneic
onstrate that lytic function is not necessary for facilita- barriers without causing GVHD. There is a long and well-
tion and that the CD8a molecule is either important established precedence for the existence of facilitative
for facilitation or in the development of facilitators. populations (Storb et al., 1968; Deeg et al., 1979; Ildstad
et al., 1986; Sykes et al., 1988). Similarly, there is a long
Introduction and well-established precedence for different hemato-
poietic populations having facilitative potential (Storb et
The search for regimens that would allow long-term al., 1968; Deeg et al., 1979; Lapidot et al., 1992; Murphy
multilineage engraftment of hematopoietic cells be- et al., 1992; Martin, 1993; Kaufman et al., 1994; Pala-
tween allogeneic individuals without severe complica- thumpat et al., 1995; Drobyski and Majewski, 1997). Lap-
tions has been a focus of hematological and immunolog- idot et al. demonstrated that CD81CD42 thymocytes
ical research for decades. Allogeneic bone marrow could enhance the engraftment of T cell±depleted mar-
engraftment has, unfortunately, been accompanied by row in the apparent absence of graft-versus-host dis-
graft-versus-host disease (GVHD), wherein donor T cells ease (Lapidot et al., 1992). Martin et al. subsequently
are involved in an often lethal multisystem immune re- demonstrated that CD81 cells from peripheral lymph
sponse against host tissues. Preclinical (Rodt et al., node (PLN) could facilitate the engraftment of T cell±
1974; Korngold and Sprent, 1978) and clinical (Filipovich depleted marrow across both major and minor histo-
et al., 1982; Prentice et al., 1982) studies suggested that compatibility barriers in irradiated recipients (Martin,
GVHD could be averted by depletion of T cells in the 1993). They were able to identify a dose of CD81 cells
hematopoietic graft. It soon became evident, however, at which facilitation was observed but at which only mild
that this had adverse consequences; namely, grafts de- and transient GVHD was detected. Clinical translation
pleted of T cells had a decreased engraftment capacity of this principle, however, has been limited; in a recent
(reviewed in Martin and Kernan, 1990). With the purifica- trial in which CD81 cells were purified by negative deple-
tion of HSC in mice (Spangrude et al., 1988), the quantita- tion of CD41 cells, a dose of CD81 cells that would allow
tive aspects of the engraftment barrier in lethally irradi- facilitation without causing GVHD was not identified
ated allogeneic recipients could be studied (Shizuru et (Martin et al., 1999). The reason for this is not yet clear.
al., 1996; Wang et al., 1997; Gandy and Weissman, Therefore, a search for a population of cells that facili-
1998; Uchida et al., 1998). Whereas 100 c-Kit1Thy1.1lo tates without causing GVHD continues. Much effort has
Lin2/loSca-11 (KTLS) HSC provide radioprotection for been directed at BM CD81 subpopulations. Kauffman
95%±100% (PD95) of lethally irradiated Ly5-congenic et al. studied subpopulations of BM for their ability to
histocompatible hosts, 1,000±2,000 KTLS are required facilitate the engraftment of hematopoietic progenitors
for radioprotection of H-2 mismatched allogeneic recipi- across allogeneic barriers (Kaufman et al., 1994). These
ents (Gandy and Weissman, 1998; Uchida et al., 1998). studies found facilitator potential in CD8a1CD8b1
TCRb2TCRgd2CD31 cells but not in CD81TCR1CD31
* To whom correspondence should be addressed (e-mail: gandy001@ cells. This contrasted with previous results in which infu-
mc.duke.edu). sion of CD81 cells from various sources (Lapidot et al.,² Present address: Duke University Medical Center, Department of
1992; Martin, 1993) (almost all of which are TCR1) hadSurgery, Box 31193, Durham, North Carolina 27710.
facilitative potential. The studies described here were³ Present address: University of Connecticut Health Center, Depart-
designed to use purified HSC and facilitators in physio-ment of Medicine, 263 Farminton Avenue, Farmington, Connecticut
06030. logical doses. The results confirm that CD81 cells
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Figure 1. Model and Evaluation of Popula-
tions of BM for Facilitator Potential
(A) Description of the model. HSC are purified
from C57BL/6, Thy-1.1 (H-2b) mice. Subpopu-
lations of BM are sorted from mice of the
same haplotype, which differ at the allelic Ly5
(CD45) marker. Mice are coinjected with 500
HSC and the number of cells in the specific
subpopulation that are found in 1 3 106 BM.
Recipient mice are lethally irradiated.
(B) Schemata for analysis of reconstitution.
As evident in (A) and as previously described,
this system allows cells of HSC, facilitator,
and host origin to be differentiated from one
another as demonstrated on the two dimen-
sional plot. All analysis is done with PI
staining.
(C) Survival at 120 days in lethally irradiated
reconstituted mice. Mice received BM, HSC,
or HSC and a subpopulation of BM as indi-
cated. One group of mice received CD81 cells
alone as controls. The p values compare ex-
perimental groups with mice receiving HSC
alone.
facilitate when used in the amounts contained in 1 3 106 that non-HSC populations within BM facilitate the en-
graftment of purified HSC across allogeneic barriers.BM and that facilitation can be detected with dosages at
Early studies have shown that mice reconstituted withwhich GVHD is not found. These studies also demon-
500 allogeneic Thy-1.1loLin2/loSca-11 (TLS) HSC hadstrate that facilitative potential is found in both CD81
lower survival rates than mice reconstituted with anTCR2CD32 and CD81TCR1CD31 populations. However,
amount of BM known to contain this number of TLSonly rare CD81TCR2CD31 cells could be found in 1 3
cells (Shizuru et al., 1996), implying that this model could106 C57BL/Ka BM, and facilitation could not be detected
serve as the basis for identifying the facilitative potentialusing the numbers present in 1 3 106 BM. Finally, facilita-
described in other model systems. In this study, to iden-tor cells were depleted in BM of CD8a2/2 mice but were
tify the populations within BM that had the ability toreplete in mice whose CD81 and NK killer function was
enhance the engraftment of purified HSC across allo-depleted. The latter findings suggest that the CD8a mol-
geneic barriers, CD41, CD81, B2201, NK-1.11, andecule but not lytic function is important in facilitation
Mac-11 populations were isolated by FACS from Ly 5.2,and/or important in the development of the potential to
C57BL/Ka donors and coinjected with HSC from Ly 5.1,facilitate.
C57BL/Ka donors (Figure 1A). As shown in Figure 1B,
three populations (HSC, putative facilitator, and host)
Results and their progeny can be differentiated in reconstituted
mice by cell surface marker staining. Figure 1C shows
CD81 Cells Enhance Survival of Mice Reconstituted the survival data from these experiments. Ten percent
with Limiting Numbers of Allogeneic HSC of mice given 500 TLS alone survived; 100% of mice
The experimental model is described in detail in Ex- given 1 3 106 BM (which contains approximately this
number of HSC) survived. The only subpopulation of BMperimental Procedures. It is based on the hypothesis
CD8 Cells Facilitate Allogeneic Engraftment of HSC
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Figure 2. The CD8a1 Population Can Be Divided into a TCRb2 and a TCRb1 Population with Facilitator Potential
(A) Top left panel shows BM stained for CD8a and TCRb. CD8a1, CD81TCR1, and CD81TCR2 cells were double sorted, with some of each
sample being collected for reanalysis (top left panels), some being sorted directly into PCR tubes for the PCR analysis (top middle panel),
and some being collected for May-GruÈ nwald-Giemsa staining (lower middle panel). Right panels show the TCRb staining of CD8lo versus CD8hi
populations of BM.
(B) Top left, host mice were reconstituted with 250±500 KTLS HSC alone, 250±500 KTLS HSC and CD81TCR2 cells, 250±500 KTLS HSC and
CD81TCR2 cells, and 250±500 KTLS HSC and CD8tot cells. Thirty day survival is shown. P values compare with mice receiving HSC alone.
Top right: host mice were reconstituted with 250 KTLS HSC alone and 250 KTLS HSC plus two different dosages of CD81TCR2 cells. Bottom
left: host mice were reconstituted with 250 KTLS HSC alone and 250 KTLS HSC plus four different dosages of CD8tot cells. Bottom right: host
mice were reconstituted with 125 or 250 KTLS HSC with or without 15,000 CD8tot cells. All hosts: lethally irradiated BALB/c.
that enhanced survival as determined by Fisher's exact The CD81 Populations Can Be Divided into TCR1
and TCR2 Populationsanalysis compared with TLS alone was the CD81 sub-
fraction (1.6 3 104 cells/injection). No mice given CD81 The CD81 population comprised 0.8%±1.8% of BM from
4- to 8-week-old mice and could be divided into(1.6 3 104 cells/injection) cells alone survived, consistent
with previous studies showing no HSC activity in the CD81TCR2 and CD81TCR1 populations by FACS (Fig-
ure 2A). The TCR1:TCR2 ratio ranged from 3:1 to 6:1.CD81 compartment (Uchida and Weissman, 1992).
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The TCRb status of these populations was confirmed by
PCR. As expected, the TCRb genes were in the germline
configuration in the cells sorted as TCR2, whereas the
TCR1 cells yielded characteristic TCRb rearrangement
products. Morphology of the cells was evaluated by
May-GruÈ nwald-Giemsa stain (Figure 2A). The TCR1 pop-
ulation resembles typical T lymphocytes. The TCR2 pop-
ulation is heterogeneous, but most cells were character-
ized by a granular cytoplasm and a low nuclear/
cytoplasm ratio. Despite the fact that these cells ap-
peared to be larger than typical lymphocytes, these pop-
ulations were not readily separated by forward or side
scatter parameters. Both were contained within stan-
dard ªlymphoid gates.º It is of note that the modal CD8a
fluorescence of the TCR2 compartment was lower than
that of the TCR1 population (Figure 2A).
The CD81TCR1 and CD81TCR2 Subpopulations of
BM Enhance the Survival of Mice Reconstituted
with Limiting Numbers of KTLS
CD81TCR2 and CD81TCR1 cells were evaluated for their
ability to facilitate HSC engraftment across allogeneic
barriers in a survival assay. In subsequent experiments
KTLS HSC (Ikuta and Weissman, 1992; Uchida et al.,
1998) were used. As previously described, the survival
of mice allogeneically reconstituted with double-sorted
KTLS cells was improved over that found with single-
sorted TLS cells (Gandy and Weissman, 1998); sur-
vival with KTLS ranges from 10%±40% after reconstitu-
tion with 250 HSC. As shown in Figure 2B, both the
CD81TCR2 and the CD81TCR1 subpopulations en-
hanced survival. Mice were given numbers of KTLS and
CD81 cells that approximated the numbers in 1 3 106
BM. However, to achieve statistically significant facilita-
tion with the CD81TCR2 cells, it was necessary to in-
crease the cell dose. When either the TCRab1 or
TCRab2 subpopulation of CD81 cells was administered
with the KTLS population in a given experiment, the
survival was less than that obtained when the total CD81
population was given with KTLS.
There is a threshold number of CD81 cells and a
threshold number of HSC below which facilitation is not
observed (Figure 2B). In the colony of mice evaluated,
the numbers were 10,000 CD81TCR2 cells or 15,000
CD8tot (CD81TCR1 and CD81TCR2). Similarly, enough
facilitation to enhance survival was not detected with
less than 250 HSC.
The CD8tot, CD81TCR1, and CD81TCR2 Populations
of BM Enhance the Reconstitution by KTLS-Derived
Populations in Allogeneic Reconstitution
Reconstitution data from PBMC analysis of the surviving
mice in one experiment are presented in Table 1. Survi-
vors are all reconstituted with predominantly HSC-derived
cells, although the levels of donor-derived cells are lower
in the populations reconstituted with KTLS alone and
KTLS 1 CD81TCR2 cells (88.5% and 82% 6 19.5%
when compared with mice reconstituted with KTLS 1
CD8a1TCR1 and KTLS 1 CD8atot (98% 6 2.4% and
99% 6 0.4%). Over 99% of Mac-11 cells in all recipient
groups are of donor origin. Reconstitution differences
are most notable in analysis of the B2201 and CD31
T
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populations. Whereas 78.5% of B2201 cells are of donor
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Figure 3. Representative Plots from Lethally Irradiated Mice Reconstituted as Indicated and Analyzed on the FACS .4 Months after Recon-
stitution
Analysis shows live gated (FSC, SSC, and PI) cells.
origin in the KTLS alone group, .92% of B2201 cells host-derived CD3 reconstitution profiles at 8 weeks are
analyzed statistically in Table 1; the differences in host-are of donor origin in mice reconstituted with KTLS and
any of the CD8 populations. More strikingly, only 10.7% derived CD31 populations between mice reconstituted
with HSC 1 CD81TCRb1 and HSC 1 CD8tot as com-and 55% 6 37.4% of CD31 cells are of HSC origin in the
KTLS alone or KTLS 1 CD81TCR2groups, respectively, pared to mice receiving HSC alone is highly significant
(p , 0.0001). As demonstrated previously, fewer host-whereas nearly all CD31 cells are donor-derived when
KTLS 1 CD81TCR1 (94% 6 5.0%) or KTLS 1 CD8tot derived CD41 and CD81 cells persist in lethally irradiated
mice after reconstitution with BM (6 3 106) as compared(95% 6 10.1%) cells are used. Related data showing lym-
phocyte analysis at a later time point are shown in the to reconstitution with comparative amounts of purified
HSC (3,000) (Gandy and Weissman, 1998), a finding sug-plots of representative animals in Figure 3. Minimal HSC-
derived CD41 and CD81 populations are detected in the gested previously by analysis of the total CD31 popula-
tion (Shizuru et al., 1996). Comparative analysis of themice reconstituted with allogeneic KTLS alone, while very
distinct populations are detected in mice receiving allo- reconstitution profiles from Figure 3 demonstrates that
this loss of host-derived populations is also detected ingeneic KTLS and the various CD81 populations (HSC-
derived T cells are in the upper right corners of the plots). the mice receiving purifed HSC and CD81 cells (TCR2,
TCR1, or both), implying that one effect of facilitator cellsAnother way of viewing the data is to evaluate the
host-derived T cell populations that persist in irradiated is to eliminate or inhibit the persistence of radioresistant
host T cells.hosts (lower right corners of the plots in Figure 3). The
Table 2. Flow Cytometric Analysis of White Blood Cell Populations in Control Mice and Lethally Irradiated and Reconstituted Mice
Blood
Cell Counts Percent B220 Percent Mac-1 CD4 Percent CD4 CD8 Percent CD8
30 Days 103/ml Ly5.11 Ly5.11 Percent of Total Ly5.11 Percent of Total Ly5.11
Control 7.0 6 1.9 NA NA 23.0 6 1.3 NA 14.1 6 0.4 NA
3,000 HSC (Ly5.1) and 6.9 6 0.7 98.0 6 2.3 99.7 6 0.1 25.7 6 8.1 56.7 6 35.5 6.5 6 1.9 66.1 6 27.3
30,000 CD81 (Ly5.2)
6 3 106 5.7 6 1.1 98.4 6 1.9 99.6 6 0.2 19.4 6 6.6 99.3 6 0.7 5.5 6 1.8 99.4 6 0.5
WBM (Ly5.11)
CD4 Percent CD4 CD8 Percent CD8
.4 Months Percent of Total Ly5.11 Percent of Total Ly5.11
C57Bl/Ka 32.9 6 4.0 99.2 6 1.2 17.5 6 2.0 98.3 6 0.9
Control
BALB/c 59.7 6 5.1 0.06 6 0.04 14.2 6 1.5 0.1 6 0.1
Control
3,000 HSC (Ly5.1) and 22.6 6 6.6 80.5 6 13.2 16.8 6 4.5 87.9 6 8.6
30,000 CD81 (Ly5.2)
6 3 106 19.3 6 4.9 79.6 6 44.5 12.3 6 2.0 95.0 6 7.0
WBM (Ly5.11)
3,000 HSC (Ly5.11) 18 81.0 6 4.7 10.0 89.0 6 2.4
Thirty days or more than 4 months after reconstitution. Host mice are BALB/c. HSC (Ly5.1), WBM (Ly5.1), and CD81 (Ly5.2) cells are C57BL/
Ka derived. Results are given as percentage of total nucleated cells (percent of total) or as percentage of HSC or WBM-derived cells (Ly5.11).
Immunity
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Figure 4. Surface Marker Characteristics of
CD8a1 Cells in BM
(A) C57BL/Ka BM was stained with CD8a,
TCRb, and one other marker. The analyses
show staining profiles of approximately 1±5 3
105 CD81 cells.
(B) Summary of CD81TCR2 and CD81TCR1
cell surface phenotypes shown in (A).
The Effect of Facilitator Cells Is Less Pronounced transplantation, donor-derived T cells had increased in
the group reconstituted with HSC and facilitators, al-at Higher Dosages of HSC
In a separate experiment, BALB/c mice were reconstitu- though the level was little different from mice reconstitu-
ted with high levels of HSC alone.ted with 3,000 C57BL/Ka, Thy-1.1 KTLS HSC, and 30,000
CD81 cells, and reconstitution was compared to that
found in mice reconstituted with 6 3 106 BM. Cell counts
35 days after transplantation demonstrated that PBMC The CD81TCR2 and CD81TCR1 Populations Are
Characterized by Distinct Cell Surface Markershad reached normal levels in mice reconstituted with
HSC plus facilitators or BM (Table 2). PBMC counts in Analyses of cell surface markers were performed on
unenriched populations to avoid skewing during selec-mice reconstituted with high doses of KTLS alone do
not approach normal levels until at least 6 weeks post- tion. Data were collected on 1±5 3 105 CD8a1 events
per analysis. Figure 4 shows the cell surface markertransplantation. The percentage of CD41, CD81, B2201,
or Mac-11 cells also approached normal levels. Over patterns of CD8a1 gated cells. Both the CD8a1TCRb1
and the CD8a1TCRb2 subpopulations are still heteroge-98% of these B2201 and Mac-11 cells were of donor
HSC origin in both groups. The percentage of CD4 and nous for other markers. The CD8a1TCRb1 cells are
CD3e1, CD21 and most are CD8b1 and CD441. TheyCD8 cells that were HSC derived, however, was only
56.8% and 66.1%, respectively, in the group reconsti- are also CD42, CD11c2, c-Kit2, and CD192. The
CD8a1TCRb1 population is heterogenous for the mark-tuted with HSC and facilitators and 99.3% and 99.4%
in the group reconstituted with BM. By 6 months post- ers B220, NK-1.1, CD16, CD38, and Sca-1 and contains
CD8 Cells Facilitate Allogeneic Engraftment of HSC
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a minor subset of IaKb1 cells. The CD8a1TCRb2 popula- molecule is required for the differentiation of bone mar-
row facilitator cells as opposed to or in addition to beingtion is CD8b2, CD11c1, and CD381, and predominantly
Thy-1.1lo, CD3e2, and c-Kit2. involved directly, the bone marrow from these mice con-
tained both TCRb1CD3e1 (CD42) cells and TCRb2CD3e2The percentage of CD81TCRb2 cells that is CD3e1
varies from 2% to 10% of the total CD81 cells. The true CD11c1IaKb1 cells in numbers approaching these sub-
sets in wild-type marrow. The number of stem cellspercentage is probably much less than this, as sorting
and resorting of this population (one way to distinguish present in CD82/2 BM was analyzed to exclude the pos-
sibility that the decreased survival was due to fewertrue events from artifacts caused by doublets, etc.) dem-
onstrated that it was very difficult to isolate CD8a1T- HSC in a given amount of BM. As can be seen in Figures
5C and 5D, there are no fewer HSC in CD82/2 BM asCRb2CD3e1 cells in appreciable numbers, with resorting
yields consistently less than 20%. This inconsistent re- determined by by day 12 CFU-S assay and cell surface
phenotype.trieval prevented further subdivision with antibodies to
markers such as TCRg or -d chains. Although the mor-
phology of CD8a1TCRb2 cells included large granular Discussion
as well as small round cells, the population was NK-1.12;
the majority of these cells had a ªlymphoidº dendritic cell Description of the Model
phenotype in that they were mainly CD11c1 and FcR Detection of facilitation is dependent upon the model.
(CD16)1 (Wu et al., 1996; Vremec and Shortman, 1997). These studies evaluated engraftment of hematopoietic
Because some cells were CD161, the 24G2 antibody cells across both major and minor histocompatibility
that blocks Fc binding was used in all stains except barriers (C57BL/Ka-Thy1.1→BALB/c) in recipients that
the 24G2 stain itself. Unfortunately, the rarity of most received a lethal dose of irradiation. It has been pre-
subsets of the CD8a1TCRb1 and CD8a1TCRb2 popula- viously determined that some T cells and NK cells persist
tions precluded their use in tests of allogeneic HSC in hosts after this conditioning regimen, although the
facilitation. number of T cells is reduced 100- to 1,000-fold (Domen
et al., 1998). Therefore, facilitation is being evaluated in
a model with persistent T and NK cells, both of whichFacilitation from CD8 Cells Deficient in Lytic Activity
IL-2-triggered CD81 T and NK cells proliferate and se- have been shown to mount a barrier to engraftment
(Dennert et al., 1985; Murphy et al., 1987; Schwartz etcrete cytokines such as TNFa and interferon-g, and a
subset goes on to cytolytic function. Cytolytically active al., 1987; Tiberghien et al., 1990; Blazar et al., 1991;
Hiruma et al., 1992; Shizuru et al., 1996). The modelNK and CD81 T cells express the functional proteases
granzyme A (GrA) and perforin (Gershenfeld and Weiss- used here was designed such that progeny derived from
facilitator, HSC, and host could be distinguished. Mostman, 1986; Hershberger et al., 1992). Transgenic mice
expressing the diptheria toxin A chain under the control reported models do not distinguish between cells of
donor-HSC and facilitator origin. This distinction is im-of the GrA promoter (GrA-DTA) produce CD8 T cells
and NK-1.1 cells that are deeply impaired in cytolytic portant in the evaluation of T cell recovery. This is also
the first reported analysis of allogeneic engraftment offunction, and the founderline used here has marked re-
ductions in the number of CD81 cells in the periphery rigorously purified HSC (KTLS) in the context of facilita-
tion. In this model, facilitation was evaluated by three(Aguila et al., 1995). However, these mice retain full bar-
rier function to transplantated allogeneic HSC (Aguila different parameters: survival, enhancement of recovery
of total donor-derived populations, and facilitated re-and Weissman, 1996). CD81 cells were sorted from the
BM of these mice and evaluated for their ability to en- moval (or loss) of residual host lymphoid cells.
The quantitative analysis of the minimal number ofhance the engraftment of 250 KTLS across allogeneic
barriers. Transgenic CD81 cells retained this potential CD8tot cells (and the TCRb2 and TCRb1 subsets) re-
quired for facilitation of 250±500 cotransplanted HSC(Figure 5A). Survival was not different between mice
reconstituted with wild-type CD8tot, GrA-DTA CD8tot, underscores a point made in three previous publications
(Shizuru et al., 1996; Gandy and Weissman, 1998; UchidaGrA-DTA CD81TCR1, and GrA-DTA CD81TCR2, though
fewer wild-type CD8tot cells were used. These studies et al., 1998): the dose of purified HSC that is both fully
radioprotective and fully engrafting in the C57BL/Ka→suggest that lytic potential is not necessary for facili-
tation. BALB/c transplant, i.e., 1,000±6,000 cells, does not en-
graft due to contaminating facilitator cells, since we show
here that the minimal dose of any CD81 (or CD81 1Bone Marrow from CD8a2/2 Mice Is Depleted
Mac-11, for that matter) population capable of facilita-of Facilitative Potential
tion of 250±500 HSC is 15±30 3 103 cells.Because CD8a1 subsets with facilitative potential are
heterogenous with respect to other cell surface markers
and morphology, it was reasonable to test the hypothe- Most Facilitator Potential Is Contained
in the CD81 Populationsis that the CD8a (and/or CD8b) molecules themselves
played a critical role in facilitation. We tested whether This study was designed to detect the most efficient
facilitator populations in BM at physiological numbers.bone marrow from CD8a2/2 mice (which also do not
express CD8b [Fung-Leung et al., 1991]) could facilitate. Initially, cells of various subpopulations were added in
the numbers present in 1 3 106 BM, which are differentAs shown in Figure 5B, C57Bl Thy-1.1 CD8a2/2 bone
marrow is at least 4±5 times less efficient at radiopro- for each population. The CD81 population, unfraction-
ated for TCRb expression, was the most efficient intecting lethally irradiated BALB/c mice than wild-type
marrow. While it is possible and likely that the CD8a facilitating both radioprotection and HSC engraftment
Immunity
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Figure 5. Facilitator Cells from Mutant Mice
(A) GrA-DTA mice. Survival at 90 days in lethally irradiated BALB/c mice reconstituted with 250 HSC and CD81 populations as indicated.
(B±D) CD82/2 mice (B). Survival at 60 days in lethally irradiated BALB/c mice reconstituted with wild-type or CD82/2 BM. (C) Analysis of CFU-S
day 12 activity of 105 wild-type BM or 105 CD82/2 BM. (D) Analysis of frequency of KTLS HSC by staining for surface markers.
of those analyzed. Analysis of these data suggests, how- was used as opposed to the Mac-1hi and Mac-1lo com-
bined. Because short-term HSC are Mac-1lo (Morrisonever, that some facilitative potential was present outside
of the CD81 population. Although analysis of Mac-11 and Weissman, 1994), it is conceivable that contaminat-
ing HSC account for this increased radioprotection. Thispopulations by Fisher's exact test were not statistically
significant, analysis of survival by Kaplan-Meier statis- finding is reminiscent of several previous studies in
which some degree of facilitation was reported in non-tics did show significant results. It is of note, however,
that the facilitation found with transfer of the Mac-1tot CD81 populations (Murphy et al., 1992; Martin, 1993;
Drobyski and Majewski, 1997). It suggests that at limitingpopulations was lost when the Mac-1hi subpopulation
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dosages of HSC, multiple populations may facilitate. complex with its MHC class I targets, perhaps by in-
creasing the avidity of cell±cell interactions (Norment etOne might question whether an increase in the number
of CD4 cells may improve facilitation. This, however, is al., 1988; Rosenstein et al., 1989; Ashton-Rickardt et
al., 1994; Luescher et al., 1995), as well as via signalnot the case, as survival was not improved in mice given
up to 80,000 CD41 cells (data not shown). transduction mechanisms (Rudd, 1990; Rudd et al.,
1991; Cai and Sprent, 1994). Mice lacking the CD8a
molecule have been described (Fung-Leung et al., 1991).The CD81TCR1 and CD81TCR2 Subpopulations
Here we demonstrated that facilitation was markedlyin Whole Bone Marrow Significantly
compromised when BM from these mice was used asbut Incompletely Facilitate
a source of facilitators. Recent data has provided evi-HSC Engraftment
dence that the CD8 complex is important in vitro in theBoth the TCR1 and TCR2 subpopulations of CD81 BM
veto effect and that cross-linking of CD8 in vitro inducescan facilitate HSC engraftment. This contrasts with the
secretion of TGFb1, which may lead to apoptosis ofstudies presented in Kaufman et al. (1994) in which the
activated alloreactive cells (Asiedu et al., 1999). MoreCD81TCR1 population of BM was not found to enhance
studies are needed to further assess the role of CD8aengraftment, but is in accordance with those of Deeg,
and its MHC class I target in facilitation.Martin, and Lapidot (Deeg et al., 1979; Lapidot et al.,
1992; Martin, 1993), in which predominantly TCR1 popu-
lations enhance HSC engraftment. The facilitative po- A Major Function of CD81 Facilitator Cells
tential found in the TCR1 cells in this study cannot be Is to Eliminate Residual Host T Cells
attributed to a contaminating TCR2 population: the pu- In earlier engraftment comparisons between a given
rity of the TCR1 populations used in these experiments amount of BM and the number of HSC contained therein
was .95%. Even if every contaminating cell in the TCR1 in the C57BL→BALB/c model of allotransplantation, we
populations were a CD81TCR2 cell (which it was not), noted that BM but not HSC eliminated residual host T
the numbers would not approach the threshold number cells (Shizuru et al., 1996). Here we demonstrate that
necessary to detect facilitation. It is of note that the the elimination of residual host T cells is a property of
number of CD81TCR1 cells used in this study was lower CD81 facilitator cells and that CD81TCR1 cells are more
than that used by Kaufman et al. (1994) and that our effective in this respect than CD81TCR2 cells. In several
facilitator populations were cotransplanted with rigor- fully allogeneic transplantation models, T cells as well
ously purified KTLS HSC. Finally, our studies utilized as NK cells can participate in barrier functions (Bennett
different mouse strains than the ones used in Kaufman et al., 1987; Murphy et al., 1987; Aguila and Weissman,
et al. (1994), and these strain variations might contribute 1996; Lee et al., 1996; Shizuru et al., 1996). In most
to the differences. studies of parent (e.g., C57BL) to F1 (e.g., [BALB/c 3
C57BL]F1) engraftment, NK cells appear to be the pre-
The Surface Phenotype of the CD81TCR2 Cells dominant cellular mediator of barrier function (Aguila
in This Study Differs from Other Studies and Weissman, 1996; Shizuru et al., 1996; Kumar et al.,
The majority of the CD81TCR2 cells in this study were 1997), although the effect of T cells has been clearly
CD32. There was a small population of CD31 cells in noted (Davenport et al., 1995). In both parent-to-F1 and
the CD81TCR2 cells, but these could not be obtained P1-to-P2 allogeneic transplants, the barrier cells do not
in significant numbers, especially since multiple sorts require granule-mediated (Baker et al., 1995; Aguila and
were necessary for purification. This result has been Weissman, 1996; Graubert et al., 1996) or FasL-medi-
confirmed by staining with CD3e antibodies originating ated (Baker et al., 1995) lytic capacity. Martin et al. have
from different hybridomas and by staining with CD3e previously demonstrated that the absence of perforin
antibodies conjugated to a variety of different fluoro- but not the absence of granzyme B significantly altered
chromes. The type of CD8 molecules on the surface of function of CD81 facilitator cells in a model of BM trans-
these cells is also noteworthy. No CD8b is detected plantation (Martin et al., 1998). They similarly demon-
by flow cytometry. These cells are probably CD8aa, a strated that the combination of deficiencies in FasL and
surface phenotype reminiscent of a population of non- granzyme B significantly reduced facilitative function.
T cells, including lymphoid dendritic cells as character- In our experiments, some facilitation is preserved in the
ized in the Shortman lab (Wu et al., 1996; Vremec and absence of cells that operate via both granzyme and
Shortman, 1997). Because these cells are also FcgR1, perforin function. Thus facilitation can occur without
false-positive staining by adhesion of Ig molecules via these cells. Due to the close temporal regulation of gran-
their Fc rather than F(ab) regions is a real possibility. zyme A, granzyme B, and perforin, activated T cells in
This was prevented by blocking with the anti-FcR mAb the GrA-DTA transgenic mice express diphtheria toxin
24G2. A and undergo apoptosis at the time of expression of
these molecules. There is an apparent discrepancy be-
tween lost perforin function leading to lost facilitatorCD8a Is Important for Facilitation
The studies that demonstrate preservation of facilitative function (Martin et al., 1998), and elimination of activated
CD81 GrA1 cells that express perforin affecting facilita-function in CD8 cells from the GrA-DTA mice suggest
that lytic function is not critical. The fact that the CD8a tion far less (this study). Perhaps the use of limiting
numbers of HSC in allogeneic transplants allows facilita-molecule was present on heterogeneous populations of
BM that had facilitative potential prompted the analysis tion to be detected at more subtle levels. Alternatively,
perforin deletion and GrA-DTA transgenes could resultof CD8a in this system. CD8 coreceptors have been
shown to play a role in the interaction of the TCRab in differences in T cell development that prevent the
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Experimental Proceduresdevelopment of facilitators in the former but not in the
latter. Operationally, facilitation resembles the veto phe-
Micenomenon, wherein MHC-bearing CD81 cells ªvetoº the
BALB/c (H-2d); C57BL/Ka, Thy-1.1, Ly-5.2 (H-2b); and C57BL/Ka,
alloreactive populations of effector cells and in so doing Thy-1.1, Ly-5.1 (H-2b) mice were maintained in the animal care facili-
enable the development of MHC-allele-specific toler- ties at Stanford. Mice were given acidified water for at least 1 week
prior to irradiation and antibiotic water (1.1 g/L neomycin sulfateance (Heeg and Wagner, 1990; Thomas et al., 1994).
and 106 U/L polymixin B sulfate) for at least 8 weeks after BMCandidate effector mechanisms for the functions of bar-
transplant to reduce the chance of infection. GrA-DTA transgenicrier cells, facilitator cells, and veto cells should include
mice were created in our lab as previously described (Aguila et al.,alternative cell death pathways such as those mediated
1995). Hematopoietic donors were 4±6 weeks of age; recipients
by LT or TNF (Ware et al., 1996), TGFb1 (Asiedu et al., were 7±12 weeks of age. For reconstitution, cells to be injected
1999), and maybe even those found in early (proto)chor- were mixed and resuspended in 100±200 ml PBS prior to retroorbital
i.v. injection.dates (Rinkevich and Weissman, 1992). The experiments
reported here now demand a careful comparison of at
least four classes of cellsÐbarrier cells, veto cells, facili- Antibodies for Cell Sorting and Analysis
tator cells, and lymphoid dendritic cellsÐall of which The rat antibodies 53-7.3 (anti-CD5), 53-6.7 (anti-CD8), Ter-119 (anti-
erythrocyte specific antigen), GK 1.5 (anti-CD4), KT 31.1 (anti-CD3),share at least some markers. Such a comparison should
6B2 (anti-B220), M1/70 (anti-Mac-1), 8C5 (anti-GR-1), 19XE5 (anti-include analyses of the lineage relationships, their ef-
Thy-1.1), E13±161 (anti-Sca-1), A20.1.7 (mouse anti-Ly5.1), and 2B8fector mechanisms, and possibly their overlapping iden-
(anti-c-Kit) were prepared from the respective clones. Antibodies
tities. were conjugated with FITC, PE, or APC. The following conjugates
were used: KT 31.1-PE, 6B2-FITC, M1/70-FITC, 8C5-PE, 19XE5-
FITC, A20.1.7-APC, and 2B8-APC. Goat anti-rat IgG-PE was ob-Clinical Implications
tained from Caltag (catalog number R40004±3). Avidin Texas redThe importance of facilitation is likely dependent on
(avidin-TR, catalog number 55894) was obtained from Cappel.the context in which it is evaluated. Facilitation in the
Stem Cell Sorting
context of reconstitution with limiting numbers of HSC HSCs were prepared as previously described. Briefly, BM was ob-
could be clinically relevant and is the subject of this tained from the tibias and femurs of adult mice. Cells were incubated
study. The importance of facilitation in the context of with antibodies against lineage markers (53-7.3, 53-6.7, Ter-119, GK
1.5, KT31.1, 6B2, M1/70, and 8C5), washed with staining media (13reconstitution with large numbers of hematopoietic cells
HBSS with 3% FCS and 10 mM HEPES [pH 7.0]), and incubatedis more controversial. It has been determined that HSC
with GAR-IgG-PE (30 min), followed by incubations with rat IgG (toalone as purified by several methods are sufficient for
occupy any nonspecific binding sites) (10 min), anti-Sca-1 (20 min),
engraftment across allogeneic barriers. Shizuru et al. avidin-MiniMacs beads (20 min), and anti-Thy-1.1-FITC and avidin-
first demonstrated that TLS HSC could fully radioprotect TR with or without anti-c-Kit-APC (20 min). Cells were passed twice
and engraft lethally irradiated hosts disparate at either through Minimacs columns (Miltenyi Biotec). Retained cells (5- to
10-fold enriched for HSC activity) were eluted and resuspended inor both major and minor histocompatibility loci and that
propidium iodide (PI)-containing media.the number of HSC required increased with the degree of
CD81 Cell Sortinghistocompatibility disparity (Shizuru et al., 1996). Other
BM was incubated with 53-6.7-biotin (20 min). Cells were then
studies utilizing the additional c-Kit marker (KTLS) in washed and incubated with avidin-MiniMacs beads (20 min). Cells
C57Bl→BALB/c mice have determined that as few as were washed and passed through a MiniMacs column as described.
1,000 HSC can save 95%±100% of lethally irradiated Cells retained in the column were eluted and incubated with AV-
PE (Caltag) or AV-TR (Pharmingen) (20 min). Cells were washed,hosts and 104 KTLS HSC lead to rapid (day 11) en-
resuspended in PI, and sorted. For sorting of the TCRb1 and TCRb2graftment of WBC and platelets, even if the more primi-
subsets of the CD8a1 cells, cells were additionally stained withtive Rh123lo subset of KTLS HSC is used (Uchida et al.,
TCRb-APC (gift of the lab of Sam Strober) or TCRb-FITC (Phar-
1998). The results of these experiments can be affected mingen) after elution from the collumn. Cells were then sorted with
by the condition of the mouse colony. Within the course the gates shown in Figure 2, 10 chanels in the TCRb axis between
of the experiments presented here, the condition of the the two populations.
mice improved such that 500 HSC, a dose which would
originally only save 20% of mice, radioprotected 40%± Strains of Mice Used for Reconstitution
80% (Gandy and Weissman, 1998). Engraftment effi- The experimental design allows for evaluation of the origin of each of
the lineages. HSC and CD8 donor mice were C57Bl/Ka Ly5 congenicciency of BM improved similarly. The three studies just
sublines, and recipients were BALB/c. C57Bl/Ka mice are H-2b hap-described evaluated allogeneic engraftment of HSC that
lotype, and BALB/c recipients are H-2d. Cells of donor facilitatorcontained both long- and short-term progenitors. Wang
origin could be differentiated from donor HSC origin by the congenic
et al. recently reported engraftment of a population char- Ly5 marker. Figure 1 shows how this method can be used to differen-
acterized in a different manner that also lacks facilitators tiate cells. Using this system, cellular progeny can be evaluated for
(Lineage2, CD712, MHC class I highly positive cells from an additional two markers on a two-laser, five-color modified FACS
Vantage, made available through the Stanford Shared FACS facility.5-FU-treated mice) and which is purported to contain
CD8a2/2 mice were generated in the lab of Tak Mak and were ob-only long-term progenitors (Wang et al., 1997). Although
tained through Jane Parnes, Stanford. These mice were back-these studies all confirm that purified HSC are sufficient
crossed 3±8 times to C57BL/Ka, Thy-1.1 mice and screened for the
to overcome the allogeneic barrier when used in large appropriate Ly5 marker for use in these experiments.
numbers, the extrapolation of allogeneic HSC 6 facilita-
tor transplants in humans of differing histocompatability
Evaluation of TCRb Gene Rearrangementdisparities is, at this point, hypothetical. If the HSC dose
Analysis of TCRb rearrangement (Db1.1 to Jb1.7 and Db2.1 to Jb2.7)
that will be available clinically is at or near the limiting by PCR was done as described (Mebius et al., 1997) on 10,000 cells
dilution for survival, then putative human facilitator cells sorted directly into 0.5% Tween D in PCR buffer. The PCR was done
as follows: 9 cycles with the external primers (30 s, 948C; 2 min,may be useful if not vital.
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tance to bone marrow grafts in mice. Biol. Blood Marrow Transplant.
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